| Imaging of Coronary Inflammation with FDG-PET: Feasibility and Clinical Hurdles. | |
| | |
MedLine Citation:
|
PMID: 21274660 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Conventional algorithms and noninvasive imaging tests for the identification of stable, hemodynamically significant coronary artery disease offer little insight into the detection of potentially vulnerable and inflamed coronary plaques, those most likely to rupture and cause acute coronary syndromes. Positron emission tomography (PET) with fluorodeoxyglucose (FDG) serves as a potential novel modality for the identification of plaque inflammation, as initial studies in animal and human studies have demonstrated that FDG uptake correlates with macrophage accumulation and inflammation. Therapy with anti-inflammatory agents has also been demonstrated in the arterial vasculature to reduce plaque FDG uptake. Although imaging of coronary inflammation with FDG-PET holds tremendous promise, several hurdles remain to be surmounted prior to widespread clinical application. |
| | |
Authors:
|
Ian S Rogers; Ahmed Tawakol |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-1-28 |
Journal Detail:
|
Title: Current cardiology reports Volume: - ISSN: 1534-3170 ISO Abbreviation: - Publication Date: 2011 Jan |
Date Detail:
|
Created Date: 2011-1-28 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100888969 Medline TA: Curr Cardiol Rep Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Division of Cardiovascular Medicine, Falk Cardiovascular Research Center, Stanford University, 300 Pasteur Drive, Stanford, CA, 94305-5406, USA, irogers@stanford.edu. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Improved FLP Recombinase, FLPe, Efficiently Removes Marker Gene from Transgene Locus Developed by Cr...
Next Document: Maladaptive Opioid Use Behaviors and Psychiatric Illness: What Should We Do with What We Know?